Avinger Reports First Quarter 2024 Results
Advances New OCT-Guided Coronary Product Development REDWOOD CITY, CA / ACCESSWIRE / May 15, 2024 / Avinger, Inc. (Nasdaq:AVGR), a...
Clinical Trial
Lynx.MD Partners with New York Gastroenterology Associates to Enhance Gastrointestinal Research Efforts
Strategic Partnership Reveals Untapped Insights in Gastroenterology Data for Research Advancement PALO ALTO, CA / ACCESSWIRE / May 15, 2024...
Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA’s Potential Market
Study to evaluate clinical effectiveness of low-dose oral interferons in treating chronic gingivostomatitis in cats, building upon VELDONA's history in...
Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA(R) Platform
OTA capability enhances introduction of new assays from rapidly expanding menuANN ARBOR, MI / ACCESSWIRE / May 15, 2024 /...
NanoViricides Has Filed its Quarterly Report
NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15,...
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR...
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived...
Tenon Medical Reports First Quarter 2024 Financial Results
~ Revenue Increased 66% Year-Over-Year ~~ Surgical Procedures Increased 42% Year-Over-Year ~~ Gross Margin Stabilized at 65% Sequentially ~~ Catamaran®...
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic...
Monogram Orthopaedics Reports First Quarter 2024 Financial Results
Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half...
Bionic Power Launches $500,000 Agilik Movement Campaign on GoFundMe
The Agilik Movement is a community-building campaign to crowdfund Agilik (TM) smart orthoses for children and teens with knee-extension deficiencies.Vancouver,...
Anumana Appoints Harry S. Palmin as CFO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#AI--Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry...
Anumana Appoints Harry S. Palmin as CFO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#AI--Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry...
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologiesSEATTLE,...
Jaguar Health Reports First Quarter 2024 Financial Results
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net...
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE /...
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile...